European Medical Solutions 과거 수익 실적
과거 기준 확인 0/6
European Medical Solutions has been growing earnings at an average annual rate of 52.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 51.4% per year.
주요 정보
52.3%
수익 성장률
84.4%
EPS 성장률
Biotechs 산업 성장 | -3.6% |
매출 성장률 | 51.4% |
자기자본 수익률 | -10.6% |
순이익 | -2.4% |
최근 수익 업데이트 | 30 Jun 2024 |
최근 과거 실적 업데이트
Recent updates
수익 및 비용 분석
European Medical Solutions 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Jun 24 | 44 | -1 | 13 | 0 |
31 Mar 24 | 43 | -1 | 13 | 0 |
31 Dec 23 | 43 | -1 | 12 | 0 |
30 Sep 23 | 41 | -1 | 12 | 0 |
30 Jun 23 | 40 | -1 | 12 | 0 |
31 Mar 23 | 38 | -3 | 12 | 0 |
31 Dec 22 | 37 | -6 | 11 | 0 |
30 Sep 22 | 66 | -7 | 19 | 0 |
30 Jun 22 | 57 | -4 | 17 | 0 |
31 Mar 22 | 48 | -2 | 14 | 0 |
31 Dec 21 | 38 | 0 | 11 | 0 |
30 Sep 21 | 0 | 2 | 1 | 0 |
30 Jun 21 | 0 | 0 | 1 | 0 |
31 Mar 21 | 0 | -1 | 1 | 0 |
31 Dec 20 | 0 | -1 | 1 | 0 |
30 Sep 20 | 0 | -5 | 2 | 4 |
30 Jun 20 | 0 | -9 | 2 | 7 |
31 Mar 20 | 1 | -12 | 3 | 10 |
31 Dec 19 | 1 | -16 | 4 | 14 |
30 Sep 19 | 1 | -16 | 3 | 13 |
30 Jun 19 | 1 | -17 | 3 | 13 |
31 Mar 19 | 1 | -16 | 3 | 12 |
31 Dec 18 | 1 | -14 | 3 | 10 |
30 Sep 18 | 1 | -12 | 3 | 10 |
30 Jun 18 | 1 | -11 | 3 | 9 |
31 Mar 18 | 1 | -11 | 2 | 10 |
31 Dec 17 | 1 | -12 | 2 | 11 |
30 Sep 17 | 1 | -12 | 2 | 11 |
30 Jun 17 | 2 | -12 | 2 | 12 |
31 Mar 17 | 2 | -12 | 2 | 12 |
31 Dec 16 | 2 | -12 | 2 | 12 |
30 Sep 16 | 1 | -12 | 2 | 11 |
30 Jun 16 | 0 | -12 | 1 | 11 |
31 Mar 16 | 0 | -10 | 1 | 9 |
31 Dec 15 | 0 | -8 | 1 | 7 |
31 Dec 14 | 0 | -4 | 1 | 3 |
31 Dec 13 | 0 | -2 | 1 | 2 |
양질의 수익: ALEMS is currently unprofitable.
이익 마진 증가: ALEMS is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: ALEMS is unprofitable, but has reduced losses over the past 5 years at a rate of 52.3% per year.
성장 가속화: Unable to compare ALEMS's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: ALEMS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
자기자본 수익률
높은 ROE: ALEMS has a negative Return on Equity (-10.58%), as it is currently unprofitable.